Sign in

NCT07220512Recruiting

The Better, Harder, Faster, Stronger Study

The BHFS Study (Better, Harder, Faster, Stronger): Does Neoadjuvant Chemotherapy Improve Fitness for Surgery?

Source: ClinicalTrials.gov · Last updated 15 Jul 2026

Brief summary (registry, in English)

The purpose of this study is to evaluate changes in the electronic Frailty Index (eFI) score following 3-4 cycles of neoadjuvant chemotherapy (NACT) in participants with advanced ovarian and endometrial cancer.

Status (registry)
Recruiting
Study type
Observational
Enrollment
35 (estimated)
First submitted
13 Oct 2025
Start date
28 Jul 2025
Primary completion date
30 Nov 2026
Lead sponsor
Wake Forest University Health Sciences
NCT number
NCT07220512

What you commit to

  • Study type: Observational
  • Planned participants: 35
  • From 28 Jul 2025 to the primary completion date, 30 Nov 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • History of poorly controlled psychiatric conditions, defined as hospitalization within the prior 3 months for psychiatric disorders, traumatic brain injury, cerebrovascular event, or dementia, per the enrolling investigator.

Other illness

  • History of brain metastases.
  • Use of anti-amyloid agents, cholinesterase inhibitors, or Memantine for Alzheimers/cognitive impairment, at the time of enrollment.
  • Vision impairment that would impede completion of study assessments, per enrolling investigator.

Who the study is looking for

  • Ability to understand and willingness to sign an IRB-approved informed consent.
  • Age \> 55 years at the time of enrollment.
  • Newly diagnosed suspected ovarian/primary peritoneal/fallopian tube carcinoma of any histological subtype, FIGO Stage II-IV, per enrolling investigator, or newly diagnosed suspected endometrial carcinoma of any histologic subtype, FIGO Stage II-IV, per enrolling investigator.
  • Planned for 3 or 4 cycles of NACT, with interval cytoreductive surgery planned thereafter.
  • Ability to read, understand, and write the English language.
  • As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study.

Age in the registry: 55 years to - · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Wake Forest Baptist Comprehensive Cancer Center
Coordinator of this site? Confirm its status
Winston-SalemUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.